

### Amendments to the Claims

1. (currently amended) An active ~~osteopontin~~ peptide fragment comprising an amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15, wherein the peptide binds to at least one integrin receptor on a cell surface of a cell, wherein the integrin receptor is selected from the group consisting of  $\alpha v \beta 3$ ,  $\alpha v \beta 5$ ,  $4 \beta 1$ ,  $2 \beta 1$ , VCAM, ICAM CD44, V3Vx.

2. (previously presented) The peptide fragment of claim 1, wherein the peptide increases cell attachment to a biomaterial and increases cell spread.

Claims 3-4. (cancelled)

5. (previously presented) The peptide fragment of claim 1 wherein the integrin(s) is selected from the group consisting of  $\alpha v \beta 3$ ,  $\alpha v \beta 5$ ,  $4 \beta 1$ , and  $2 \beta 1$ .

6. (previously presented) The peptide fragment of claim 1 wherein the cell is selected from the group consisting of osteoprogenitor cells, tumor cells, macrophages, periosteal cells, endothelial cells, epithelial cells, eosinophils, stem cells, limited potential precursor cells, precursor cells, committed precursor cells, and differentiated cells.

Claims 7-18 (cancelled)